|Transporter-based In Vitro-In Vivo Extrapolation (IVIVE)|
Viera Lukacova, Michael B. Bolger, Walter S. Woltosz, Neil J. Parrott, Agnès Poirier and T. Lavè
Mechanistic analysis of in vitro measurements to obtain values of kinetic parameters for drug interactions with transporters, as well as for passive diffusion through cell membranes.
|Classification of Drugs by CNS Access: An Insight from Quantitative Blood-Brain Transport Characteristics|
Kiril Lanevskij, Pranas Japertas and Remigijus Didziapetris, Advanced Chemistry Development Inc.
Aim of this study was to identify relationships between quantitative blood-brain transport parameters and qualitative data indicating whether the compound penetrates into the brain efficiently enough to exhibit action in the CNS.
|An In Silico Test Battery for Rapid Evaluation of Genotoxic and Carcinogenic Potential of Chemicals|
Kiril Lanevskij, Liutauras Juska, Justas Dapkunas, Andrius Sazonovas, Pranas Japertas and Remigijus Didziapetris, of ACD/Labs and Vilnius University
The FDA guidance for industry states impurities under the ICH threshold may be exaluated for genotoxicity and carcinogenicity. This study uses an expert system to detect mutagens and compounds labeled as potent carcinogens by the FDA.
|A Systematic Review of Lifestyle Modification in Adults with Non-Alcoholic Fatty Liver Disease|
C. Thoma, C. P. Day and M. I. Trenell, Newcastle University
This study reviews the causes of non-alcoholic fatty liver disease and the associated risk factor for type 2 diabetes and cardiovascular disease.
|Cytotoxicity Screen of Mangiferin and its Major Metabolite Norathyriol in Human Tumor Cell Lines|
Souza, J.R.R., Feitosa, J.P.A., Ricardo, N.M.P.S, Trevisan, M.T.S., Frei, E., Ulrich C.M., Owen, R.W.
Many natural products are available worldwide as potential chemoprotective agents against commonly occurring cancers, for example Mangiferin which has low bioavailability and is thought to be mainly available in the colon.
|ASSESSMENT OF A MICROPATTERNED HEPATOCYTE CO-CULTURE SYSTEM TO DETECT COMPOUNDS THAT CAUSE DRUG INDUCED LIVER INJURY IN HUMANS|
Salman Khetani, Chitra Kanchagar, Stacy Krzyzewski, Michael D. Aleo and Yvonne Will
This case study demonstrates the increased success of Hepregen’s novel micro-patterned co-culture system in identifying primary and secondary circulating and excretory metabolites when compared to liver microsomes, S-9 fractions and primary human hepatocyte suspensions for a series of 27 compounds with known in vivo human metabolite profiles.
|Nanoliter Volume Pin Tool Transfers as Measured by a Dual-Dye Absorbance Method|
Duong T. Chau; Patrick H. Cleveland, Ph.D.; John Thomas Bradshaw, Ph.D.
Increasing costs of chemical compounds and commonly used solvents has pushed high throughput screening labs towards lower working volumes, specifically in the nanoliter range. The ability to controllably dispense “known” nanoliter aliquots of samples is desired, which can readily be achieved using Pin Tools.
|Why Is My Assay Failing? An Approach to Assay Equipment Optimization|
Tanya R. Knaide, John Thomas Bradshaw, Kevin Khovananth, Keith Albert
Assays can produce unexpected or failing results for a multitude of reasons. Variability may be introduced at any point within the assay process.
|Validation of an Automated Cell-Based Bioluminescent TNFa Blocker Bioassay|
Brad Larson, Tracy Worzella, Rich Moravec, Neal Cosby, Frank Fan, Teresa Surowy and Peter Banks
TNFa blocker biopharmaceuticals represent an important and successful class of protein drugs used in the treatment of several autoimmune diseases. Bioassays are indispensible tools in biopharmaceutical drug development and commercialization that are used to quantify biological activity and stability of drugs or drug candidates. The automation of these assays can serve to create an accurate, robust process which can allow the researcher to perform other more important functions.